Matches in Nanopublications for { ?s ?p "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP265933.RAii4GZ1MrEowllqZO3cPJvG8wrSl6Wj315W-LIQozAy4130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP265933.RAii4GZ1MrEowllqZO3cPJvG8wrSl6Wj315W-LIQozAy4130_provenance.
- NP1004744.RAjPWOAIdJQh1hrb82qe8T8UpdBaLylfGDAQQ4mZIIaTg130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1004744.RAjPWOAIdJQh1hrb82qe8T8UpdBaLylfGDAQQ4mZIIaTg130_provenance.
- NP1383143.RAjqsrLIokeFcbgPMAbEv1KecbT3e-Bt92P0tCN9H7VuY130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1383143.RAjqsrLIokeFcbgPMAbEv1KecbT3e-Bt92P0tCN9H7VuY130_provenance.
- NP1383147.RAkkPln2qrCRCGxu-n5pcqGnVIY9Atcr2_CM1LLRpHakw130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1383147.RAkkPln2qrCRCGxu-n5pcqGnVIY9Atcr2_CM1LLRpHakw130_provenance.
- NP1383148.RArliNAPrc9qC64b0YOKbU9mtWAqO8eJeq8pnUsefwSJk130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1383148.RArliNAPrc9qC64b0YOKbU9mtWAqO8eJeq8pnUsefwSJk130_provenance.
- NP991483.RAyKWcobm5_bxBdpxrbdaxpK_NwZBMPl8cyWTIzFkPvUs130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP991483.RAyKWcobm5_bxBdpxrbdaxpK_NwZBMPl8cyWTIzFkPvUs130_provenance.
- NP1004778.RA5JqvNADgHw3ir_Ev45az9TTU6a-lqJddijjlVUAApfE130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1004778.RA5JqvNADgHw3ir_Ev45az9TTU6a-lqJddijjlVUAApfE130_provenance.
- NP1383149.RAOGR2pklbIBp7E8f4iSdTWythm-w7Ll4GkNaShx5ONYw130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1383149.RAOGR2pklbIBp7E8f4iSdTWythm-w7Ll4GkNaShx5ONYw130_provenance.
- NP1383145.RA_NulOWhC2NDqRoq-bjyExkwwLbRkUZXdjtCJ1qHho2U130_assertion description "[Because the epitope identified by PG-M3 is located in the aminoterminal portion of PML (AA 37 to 51), the antibody was suitable for recognizing APL cases characterized by breakpoint occurring at different sites of PML (bcr 1, bcr 2 and bcr 3).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1383145.RA_NulOWhC2NDqRoq-bjyExkwwLbRkUZXdjtCJ1qHho2U130_provenance.